Marshall Wace LLP Invests $441,000 in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Marshall Wace LLP purchased a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 94,537 shares of the company’s stock, valued at approximately $441,000. Marshall Wace LLP owned 0.17% of Black Diamond Therapeutics as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Ally Bridge Group NY LLC purchased a new stake in shares of Black Diamond Therapeutics in the second quarter valued at $3,891,000. Renaissance Technologies LLC boosted its holdings in Black Diamond Therapeutics by 24.1% during the 2nd quarter. Renaissance Technologies LLC now owns 263,900 shares of the company’s stock valued at $1,230,000 after acquiring an additional 51,300 shares during the period. Dimensional Fund Advisors LP grew its position in Black Diamond Therapeutics by 79.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 200,044 shares of the company’s stock valued at $932,000 after acquiring an additional 88,378 shares during the last quarter. TD Asset Management Inc increased its stake in Black Diamond Therapeutics by 275.9% in the second quarter. TD Asset Management Inc now owns 266,312 shares of the company’s stock worth $1,241,000 after purchasing an additional 195,464 shares during the period. Finally, Foundations Investment Advisors LLC lifted its position in shares of Black Diamond Therapeutics by 17.7% during the second quarter. Foundations Investment Advisors LLC now owns 113,550 shares of the company’s stock worth $529,000 after purchasing an additional 17,050 shares during the last quarter. 95.47% of the stock is currently owned by institutional investors.

Black Diamond Therapeutics Trading Down 3.1 %

Shares of NASDAQ:BDTX opened at $3.44 on Friday. The company has a market capitalization of $193.51 million, a PE ratio of -2.07 and a beta of 2.47. Black Diamond Therapeutics, Inc. has a 12-month low of $1.62 and a 12-month high of $7.66. The business’s fifty day simple moving average is $5.13 and its 200-day simple moving average is $5.29.

Black Diamond Therapeutics (NASDAQ:BDTX) last posted its earnings results on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Research analysts predict that Black Diamond Therapeutics, Inc. will post -1.4 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a research note on Wednesday. Piper Sandler lifted their price target on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, September 23rd. Raymond James started coverage on Black Diamond Therapeutics in a research note on Wednesday, July 31st. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Black Diamond Therapeutics in a report on Tuesday.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.